Bionano Genomics Announces Participation at the European Society of Human Genetics Conference (ESHG) 2022 Featuring OGM Across a Broad Range of Clinical Research Applications and a Collaborative Product Development with Hamilton
- The Long String VANTAGE for DNA isolation, a collaborative development between Bionano and Hamilton, and the world’s first automation solution for Ultra High Molecular Weight (UHMW) extraction used in optical genome mapping (OGM), will be on display at the conference
- A corporate satellite presentation by Dr.
Detlef Trost , Laboratoire CERBA, and Dr. Alexander Hoischen, Radboud UMC, will cover the latest research on OGM for rare undiagnosed genetic disease (RUGD) discovery - Three featured scientific presentations, one each by Dr.
Claudia Carvalho ,Pacific Northwest Research Institute , Dr. Laïla El Khattabi, HôpitalCochin , and Dr.Kornelia Neveling , Radboud UMC, will cover the use of OGM in research on complex genomic rearrangement structures, characterization of structural variations (SVs), and on repeat expansion disorder testing, respectively - 9 scientific poster presentations and e-posters will illustrate the application of Bionano’s OGM solutions in constitutional disorders and RUGD diagnosis
ESHG is an annual conference that brings together industry and academic professionals to discuss new technologies and advances in the field of human genetics. ESHG sessions will take place June 11-14, 2022 virtually and in
Bionano and Hamilton jointly announced the Long String VANTAGE, which is the first Assay Ready Workstation solution in Hamilton´s Long String Genomics product program which supports extraction of UHMW DNA at increased scale. Attendees at ESHG will be able to learn more about the Long String VANTAGE at both companies’ booths and can experience a demonstration of the workflow at Hamilton’s booth throughout the conference.
As part of a corporate satellite presentation, Dr.
Three genomics researchers will participate in separate featured scientific presentations, highlighting use of OGM in genetic disorder testing. Dr.
Scientific presentations and poster sessions from Bionano and customers include:
Room | Title | Presenter | Presented |
ACV, Room G, Level-2 | See More, Know More: How OGM Provides Answers for Rare Undiagnosed Genetic Disease | Trost D., Hoischen A., Delpu Y. | |
Hall E-2, Concurrent Symposia S05 | S05.2: Identification of Complex Genomic Rearrangement Structures in Disease | Carvalho C. | |
Hall E2-Workshop: What’s New in Cytogenomics? | W12: Optical Genome Mapping Enables Next-Generation Cytogenetics | ||
Hall E2- Concurrent Sessions C27 | C27.3: Optical Genome Mapping for Repeat Expansion Disorder Testing | Neveling K. | |
Poster | Title | Author | Presented |
P15.004.A | Structural and copy number variant detection, filtering, annotation, and classification by optical genome mapping in constitutional disorders | Delpu Y. | Poster Session |
P11.010.A | FSHD analysis pipeline by Bionano optical genome mapping: A field report | Heinrich U. | Poster Session |
P13.107.A | An insertion in the MSH2 gene detected by Bionano optical mapping and confirmed by Nanopore sequencing in a family with suspected Lynch Syndrome | Aaløkken R. | Poster Session |
P09.027.C | Optical genome mapping analysis of FMR1 expansions in fragile X syndrome and multi-site validation | Venier A. | Poster Session |
P15.003.D | Comparative benchmarking of optical genome mapping and chromosomal microarray reveals high technological concordance in CNV identification and structural variant refinement | Jaber D. | Poster Session |
P16.020.D | Optical genome mapping in routine human genetic diagnostics: Lessons learned | Dremsek P. | Poster Session |
P16.032.D | Optical Genome Mapping as a diagnostic tool in cases of unresolved rare diseases | Trost D. | Poster Session |
EP15.018 | A paracentric inversion that disrupts the SHANK2 gene resolved using cytogenomics | Huyghebaert J. | E-Poster |
EP15.002 | Recurrent constitutional chromosome five inversion revisited | Doco-Fenzy M. | E-Poster |
More details on the conference can be found here.
“We are thrilled to see the broad range of presentations featuring OGM at ESHG this year. These institutions and their research teams have conducted innovative research to help demonstrate the potential utility of OGM as a more sensitive, faster and less expensive alternative to traditional cytogenetics methods,” commented
About
Forward-Looking Statements of
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “potential,” “can,” “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the potential contribution of our OGM solutions to offer the anticipated benefits for and contributions to the areas reported in the presentations given and posters made available at the ESHG Annual Meeting; anticipated benefits and improvements resulting from the use of Long String VANTAGE to reliably and consistently isolate high quality and sufficient quantity of UHMW DNA for use with OGM . Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; the ability of our OGM solutions to offer the anticipated benefits for and contributions to the areas of research reported in the presentations given and posters made available at the ESHG Annual Meeting; future study results contradicting the results reported in the presentations given and posters made available at the ESHG Annual Meeting; the ability of Long String VANTAGE system to reliably and consistently isolate high quality and sufficient quantity of UHMW DNA for use with OGM; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the
CONTACTS
Company Contact:
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations:
+1 (858) 366-3243
amy@juniper-point.com
Source: Bionano Genomics